174 related articles for article (PubMed ID: 32653454)
1. Biologic Implications of t(11;14) in Multiple Myeloma Explained With a Case of Refractory Disease Sensitive to Venetoclax.
Soleimani A; Koka M; Singh ZN; Kesari V; Badros A
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e556-e559. PubMed ID: 32653454
[No Abstract] [Full Text] [Related]
2. Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma.
Boccon-Gibod C; Talbot A; Le Bras F; Frenzel L; Royer B; Harel S; Lombion N; Belhadj K; Cuccuini W; Arnulf B
Br J Haematol; 2020 May; 189(3):e73-e76. PubMed ID: 32012229
[No Abstract] [Full Text] [Related]
3. Venetoclax for the treatment of multiple myeloma.
Vaxman I; Sidiqi MH; Gertz M
Expert Rev Hematol; 2018 Dec; 11(12):915-920. PubMed ID: 30428277
[No Abstract] [Full Text] [Related]
4. Venetoclax in a Patient With Light Chain Deposition Disease Secondary to MGRS That Progressed After Kidney Transplantation.
Leung N; Dingli D
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e488-e491. PubMed ID: 32466980
[No Abstract] [Full Text] [Related]
5. Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma.
Matulis SM; Gupta VA; Neri P; Bahlis NJ; Maciag P; Leverson JD; Heffner LT; Lonial S; Nooka AK; Kaufman JL; Boise LH
Leukemia; 2019 May; 33(5):1291-1296. PubMed ID: 30679802
[No Abstract] [Full Text] [Related]
6. Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).
Touzeau C; Le Gouill S; Mahé B; Boudreault JS; Gastinne T; Blin N; Caillon H; Dousset C; Amiot M; Moreau P
Haematologica; 2017 Mar; 102(3):e112-e114. PubMed ID: 28057737
[No Abstract] [Full Text] [Related]
7. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
Abuelgasim KA; Alherz N; Alhejazi A; Damlaj M
J Med Case Rep; 2020 Apr; 14(1):54. PubMed ID: 32321588
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.
Kumar S; Kaufman JL; Gasparetto C; Mikhael J; Vij R; Pegourie B; Benboubker L; Facon T; Amiot M; Moreau P; Punnoose EA; Alzate S; Dunbar M; Xu T; Agarwal SK; Enschede SH; Leverson JD; Ross JA; Maciag PC; Verdugo M; Touzeau C
Blood; 2017 Nov; 130(22):2401-2409. PubMed ID: 29018077
[TBL] [Abstract][Full Text] [Related]
9. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
Kitadate A; Terao T; Narita K; Ikeda S; Takahashi Y; Tsushima T; Miura D; Takeuchi M; Takahashi N; Matsue K
Cancer Sci; 2021 Sep; 112(9):3645-3654. PubMed ID: 34288263
[TBL] [Abstract][Full Text] [Related]
10. Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma.
Algarín EM; Quwaider D; Campos-Laborie FJ; Díaz-Tejedor A; Mogollón P; Vuelta E; Martín-Sánchez M; San-Segundo L; González-Méndez L; Gutiérrez NC; García-Sanz R; Paíno T; De Las Rivas J; Ocio EM; Garayoa M
Cells; 2021 Mar; 10(3):. PubMed ID: 33806619
[TBL] [Abstract][Full Text] [Related]
11. Secondary plasma cell leukaemia treated with single agent venetoclax.
Glavey SV; Flanagan L; Bleach R; Kelly C; Quinn J; Ní Chonghaile T; Murphy P
Br J Haematol; 2020 Aug; 190(4):e242-e245. PubMed ID: 32525557
[No Abstract] [Full Text] [Related]
12. Targeting Bcl-2 for the treatment of multiple myeloma.
Touzeau C; Maciag P; Amiot M; Moreau P
Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
[TBL] [Abstract][Full Text] [Related]
13. BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma.
Dousset C; Maïga S; Gomez-Bougie P; Le Coq J; Touzeau C; Moreau P; Le Gouill S; Chiron D; Pellat-Deceunynck C; Moreau-Aubry A; Amiot M
Br J Haematol; 2017 Nov; 179(4):684-688. PubMed ID: 27471002
[No Abstract] [Full Text] [Related]
14. Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials.
Avigan ZM; Joshua Richter Md
Oncology (Williston Park); 2024 Jun; 38(6):239-241. PubMed ID: 38899981
[TBL] [Abstract][Full Text] [Related]
15. Use of venetoclax in t(11;14) positive relapsed/refractory multiple myeloma: A systematic review.
Khan WJ; Ali M; Hashim S; Nawaz H; Hashim SN; Safi D; Inayat A
J Oncol Pharm Pract; 2024 Apr; 30(3):552-561. PubMed ID: 38113108
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.
Wierda WG; Byrd JC; Davids MS; Furman RR; Cheson BD; Barr PM; Eradat H; Heffner L; Zhou L; Verdugo M; Potluri J; Choi M
Br J Haematol; 2019 Jun; 185(5):961-966. PubMed ID: 30478940
[No Abstract] [Full Text] [Related]
17. Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects.
AlZahrani A; Alsuhebany N; Tailor IK; Alrajhi AM
Hematology; 2024 Dec; 29(1):2296809. PubMed ID: 38149670
[TBL] [Abstract][Full Text] [Related]
18. Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.
Shoumariyeh K; Jung J; Rassner M; Dold SM; Riebl V; Pantic M; Herget G; Marks R; Lübbert M; Wäsch R; Engelhardt M
Ann Hematol; 2021 Jun; 100(6):1637-1640. PubMed ID: 33712868
[No Abstract] [Full Text] [Related]
19. Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma.
Bajpai R; Sharma A; Achreja A; Edgar CL; Wei C; Siddiqa AA; Gupta VA; Matulis SM; McBrayer SK; Mittal A; Rupji M; Barwick BG; Lonial S; Nooka AK; Boise LH; Nagrath D; Shanmugam M
Nat Commun; 2020 Mar; 11(1):1228. PubMed ID: 32144272
[TBL] [Abstract][Full Text] [Related]
20. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
Moreau P; Chanan-Khan A; Roberts AW; Agarwal AB; Facon T; Kumar S; Touzeau C; Punnoose EA; Cordero J; Munasinghe W; Jia J; Salem AH; Freise KJ; Leverson JD; Enschede SH; Ross JA; Maciag PC; Verdugo M; Harrison SJ
Blood; 2017 Nov; 130(22):2392-2400. PubMed ID: 28847998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
